495
edits
Changes
ACMG technical standards and guidelines: microarray analysis for chromosome abnormalities in neoplastic disorders (2013) (view source)
Revision as of 16:54, 27 July 2016
, 16:54, 27 July 2016→Reporting Guidelines for Microarray Analysis of Neoplastic Disorders
The following guidelines describe the elements of the clinical report that are necessary to communicate clearly and completely the clinical significance of microarray analysis results.
The following guidelines describe the elements of the clinical report that are necessary to communicate clearly and completely the clinical significance of microarray analysis results.
Reporting criteria
'''Reporting criteria'''
Microarray reports should be written so the result is understandable to a nongeneticist health-care provider and so that the clinical significance of the result for patient management is clear.
Microarray reports should be written so the result is understandable to a nongeneticist health-care provider and so that the clinical significance of the result for patient management is clear.
Verbal discussion of microarray results with the health-care provider is encouraged to facilitate communication and understanding of microarray results and clinical significance.
Verbal discussion of microarray results with the health-care provider is encouraged to facilitate communication and understanding of microarray results and clinical significance.
Written report
'''Written report'''
The written report should include the following:
The written report should include the following:
#Date of final report.
#Date of final report.
#Disclaimers as appropriate, e.g., when and what investigational procedures are employed. Disclaimers as required.
#Disclaimers as appropriate, e.g., when and what investigational procedures are employed. Disclaimers as required.
== Conclusions ==
== Conclusions ==